Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Look what's coming - verrry interesting ---
Excerpts -
SAN DIEGO, Aug. 19, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Momenta Pharmaceuticals, Inc. ("Momenta" or the "Company") (NASDAQ: MNTA) breached their fiduciary duties in connection with the proposed sale of the Company to Johnson & Johnson (NYSE: JNJ).
The investigation concerns whether the Momenta board failed to satisfy its duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for Momenta shares of common stock.
If you are a shareholder of Momenta and believe the proposed buyout price is too low or you're interested in learning more about the investigation, please contact....
https://finance.yahoo.com/news/mnta-alert-johnson-fistel-investigates-113800467.html
Thank you, Urche. For the past 10 years+, it's been BLOOD, SWEAT & FEARS.
Personally, I want to thank - DEW. His past advice led me to BELIEVE.
Notice that the stock is now trading above $52.50 and the BOD entered into a "definitive agreement" - might another company bid higher?
Also, 8M shorts - what's with that?!!
We've worked long & hard - LONGS deserve this fortunate result!
Momenta Pharmaceuticals' stock rockets after $6.5 billion buyout deal with Johnson & Johnson
https://www.marketwatch.com/story/momenta-pharmaceuticals-stock-rockets-after-65-billion-buyout-deal-with-johnson-johnson-2020-08-19?siteid=yhoof2&yptr=yahoo
CONGRATULATION to all MNTA LONGS!!!!
Momenta Enters Definitive Agreement with Johnson & Johnson
Johnson & Johnson to acquire Momenta for $52.50 per share in cash, representing a total equity value of $6.5 billion and a 70% premium to Momenta’s closing price on August 18, 2020
Momenta’s FcRn inhibitor, nipocalimab, has the potential to transform treatment of autoantibody-driven autoimmune diseases
Transaction expected to be completed in the second half of 2020
CAMBRIDGE, Mass., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA, “Momenta” or the “Company”), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases announced today that it has entered into a definitive agreement for Johnson & Johnson (“Johnson & Johnson” or “J&J”) to acquire Momenta for $52.50 per share in an all-cash transaction, implying a fully-diluted equity value of $6.5 billion. The agreement was unanimously approved by the Boards of Directors of both Momenta and Johnson & Johnson.
"The agreement with J&J recognizes the value created by years of commitment and dedication to our mission by the many current and past Momenta employees. Programs such as nipocalimab have the potential to improve the lives of countless patients suffering from autoimmune and fetal maternal diseases,” said Craig Wheeler, President and Chief Executive Officer of Momenta. “This acquisition provides strong value for our shareholders and ensures a level of investment in our exciting portfolio that will further enhance its potential for patients. I believe J&J is the right company to advance our portfolio of novel drug candidates for autoimmune and rare diseases. J&J’s leadership in immunology, extensive capabilities, and global reach, as well as its alignment with our vision of pioneering therapies for complex diseases is a strong fit for our company and our portfolio.”
The transaction is expected to close in the second half of 2020, pending the satisfaction of all conditions to the completion of the tender offer and merger. Until that time, Momenta will continue to operate as a separate and independent company.
Momenta’s financial advisors are Goldman Sachs & Co. LLC and Centerview Partners LLC, Latham & Watkins LLP is acting as legal counsel for Momenta and Skadden, Arps, Slate, Meagher & Flom LLP is acting as legal counsel for Goldman Sachs & Co. LLC and Centerview Partners LLC.
Transaction Details
Under and subject to the terms of the agreement, Vigor Sub, Inc. (“Merger Sub”), a newly formed wholly owned subsidiary of Johnson & Johnson, agreed to commence a tender offer to acquire all outstanding shares of Momenta common stock for $52.50 per share in cash and Momenta agreed to file a recommendation statement containing the unanimous recommendation of the Momenta board that Momenta stockholders tender their shares to Merger Sub. Following the completion of the tender offer, Johnson & Johnson expects to promptly consummate a merger of Momenta with Merger Sub, in which shares of Momenta that have not been tendered in the tender offer will be acquired by Johnson & Johnson and converted into the right to receive the same cash price per share as paid in the tender offer.
The closing of the tender offer is subject to customary closing conditions, including the tender of a majority of outstanding Momenta shares on a fully diluted basis and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The merger agreement includes customary termination provisions for both Momenta and Johnson & Johnson.
Thank you Mr. T -
All our MNTA friends - CONGRATULATIONS!!!!!!
Momenta Enters Definitive Agreement with Johnson & Johnson
Johnson & Johnson to acquire Momenta for $52.50 per share in cash, representing a total equity value of $6.5 billion and a 70% premium to Momenta’s closing price on August 18, 2020
Momenta’s FcRn inhibitor, nipocalimab, has the potential to transform treatment of autoantibody-driven autoimmune diseases
Transaction expected to be completed in the second half of 2020
CAMBRIDGE, Mass., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA, “Momenta” or the “Company”), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases announced today that it has entered into a definitive agreement for Johnson & Johnson (“Johnson & Johnson” or “J&J”) to acquire Momenta for $52.50 per share in an all-cash transaction, implying a fully-diluted equity value of $6.5 billion. The agreement was unanimously approved by the Boards of Directors of both Momenta and Johnson & Johnson.
"The agreement with J&J recognizes the value created by years of commitment and dedication to our mission by the many current and past Momenta employees. Programs such as nipocalimab have the potential to improve the lives of countless patients suffering from autoimmune and fetal maternal diseases,” said Craig Wheeler, President and Chief Executive Officer of Momenta. “This acquisition provides strong value for our shareholders and ensures a level of investment in our exciting portfolio that will further enhance its potential for patients. I believe J&J is the right company to advance our portfolio of novel drug candidates for autoimmune and rare diseases. J&J’s leadership in immunology, extensive capabilities, and global reach, as well as its alignment with our vision of pioneering therapies for complex diseases is a strong fit for our company and our portfolio.”
The transaction is expected to close in the second half of 2020, pending the satisfaction of all conditions to the completion of the tender offer and merger. Until that time, Momenta will continue to operate as a separate and independent company.
Momenta’s financial advisors are Goldman Sachs & Co. LLC and Centerview Partners LLC, Latham & Watkins LLP is acting as legal counsel for Momenta and Skadden, Arps, Slate, Meagher & Flom LLP is acting as legal counsel for Goldman Sachs & Co. LLC and Centerview Partners LLC.
Analysts left this out of their Q & A - BUT, we know & now - word is circulating -
Momenta exploring utility of necuparanib for COVID-19 The Company is currently exploring the utility of necuparanib, a former novel oncology candidate, as a potential therapy for treating COVID-19. The Company has confirmed the ability of necuparanib to bind to the SARS-Cov2 spike protein and is assessing the potential to block viral infection of respiratory epithelial cells. As multiple respiratory viruses are believed to utilize binding to heparin sulfate glycoproteins on cells to facilitate infection, the Company is assessing the ability of necuparanib to block cell infection by other coronavirus and respiratory viruses. The Company anticipates completing the initial cell infection studies in the coming weeks.
Read more at:
https://thefly.com/landingPageNews.php?id=3143207
Momenta's nipocalimab potential best-in-class, says Piper Sandler 10:47 MNTA Piper Sandler analyst Tyler Van Buren reiterated an Overweight rating on Momenta shares as he believes the M254/ITP and nipocalimab/gMG updates through year-end will be positive and provide significant returns for investors. The analyst continues to believe nipocalimab is a potential best-in-class anti-FcRn mAb and says current data support a 1x monthly infusion, which could be a significant competitive advantage.
Read more at:
https://thefly.com/landingPageNews.php?id=3143548
Your questions are good ones. However, I can NOT factually answer hypotheticals since specific MNTA Neco-Covid data has not been generated nor FDA labeled.
Similarly - What’s still unknown at this point re:REMDESIVIR ?
Experts are encouraged by the moderate benefits described in the NIH press release, but they said without seeing all the data, it’s still hard to know how best to use remdesivir. Does the efficacy of the drug depend on severity of illness? Is it more effective if given earlier?
“Likely the benefit of any anti-viral is when you give it early in infection to stop viral replication,” said Yang.
https://www.ucsf.edu/news/2020/05/417436/antiviral-drug-remdesivir-can-help-fight-coronavirus-can-patients-get-it
NECUPARANIB - COVID
Next, I'd like to share an update on our exploration of the potential benefit of necuparanib to help fight COVID. On our MG call in June, we disclosed that we were researching necuparanib, a novel drug candidate we had previously tested in pancreatic cancer to evaluate if it could block the COVID-19 virus by binding to the spike protein.
Recent academic publications have reported a demonstrated therapeutic rationale for heparin-based drugs, potentially delivering strong antiviral activity in addition to the established anticoagulant and anti-inflammatory properties of heparins. In laboratory assays, heparin was reported to deliver up to four times more potency in blocking the ability of SARS-CoV2 to infect respiratory cells when compared with Gilead's remdesivir. If our drug shows similar benefits to other heparins being tested in the clinic, we believe it could have multiple advantages, including, first, necuparanib was designed to be a low molecular weight agent that retains many of the protein-binding properties with heparin but without the anticoagulant binding sequence. The low molecular weight could provide many advantages, including reliable subcu PK and potentially a nebulized delivery to the lung, if nebulized drug is needed.
Second, one of the big drawbacks of most heparins is that they are anticoagulants, so they cannot be dosed at high levels, as they will cause bleeding. Our agent is a non-anti-coagulant heparin derivative designed to be used in high doses for cancer patients without causing excessive anticoagulation.
Third, our agent already has a full toxicology package, GMP manufacturing supply chain for drug substance and drug product and demonstrated safety in Phase 1 and 2 clinical trials. So, it could be about faster than other new agents being tested.
To-date, we have confirmed the ability of necuparanib to bind the SARS-Cov2 spike protein, which is the protein used by the coronavirus to enter and infect cells. We have now begun cell-based assays with test viruses to see if necuparanib can block viral infection of the cell. We have seen a strong ability to block infections using RSV as a test virus, and now have advanced to testing the drug with coronaviruses. We're excited with the progress to-date and we'll keep you updated.
Momenta Pharmaceuticals Inc (MNTA) Q2 2020 Earnings Call Transcript
https://finance.yahoo.com/quote/MNTA/?p=MNTA
Momenta share weakness a buying opportunity, says Stifel Stifel analyst Derek Archila reiterated a Buy rating and $47 price target on Momenta Pharmaceuticals, saying he thinks the shares are "weak" based on some of management's commentary from the company's Q2 earnings call. Archila noted that management highlighted that it has already initiated part C of the M254's Phase 1/2 study and noted that part B demonstrated consistent results to what they reported earlier this year on response and durability. The analyst added, however, that management commented that the comparison of M254 versus traditional IVIG was "puzzling." Archila said that he'd be a buyer on the weakness in shares.
Read more at:
https://thefly.com/landingPageNews.php?id=3143654
Momenta share weakness a buying opportunity, says Stifel
Read more at:
https://thefly.com/landingPageNews.php?id=3143654
Momenta's nipocalimab potential best-in-class, says Piper Sandler »
Read more at:
https://thefly.com/landingPageNews.php?id=3143548
Amongst the 2Q report -
Necuparanib (M402): The Company is currently exploring the utility of necuparanib (M402), a former novel oncology candidate, as a potential therapy for treating COVID-19. The Company has confirmed the ability of necuparanib (M402) to bind to the SARS-Cov2 spike protein and is assessing the potential to block viral infection of respiratory epithelial cells. As multiple respiratory viruses are believed to utilize binding to heparin sulfate glycoproteins on cells to facilitate infection, the Company is assessing the ability of necuparanib to block cell infection by other coronavirus and respiratory viruses. The Company anticipates completing the initial cell infection studies in the coming weeks.
Momenta upgraded to Outperform from Market Perform at Cowen 06:14 MNTA
Read more at:
https://thefly.com/landingPageNews.php?id=3137355
Momenta Pharmaceuticals (MNTA) Well Positioned Ahead of M254 Phase I/II Part B Update - Piper Sandler.... 29 July
Piper Sandler analyst Tyler Van Buren reiterated an Overweight rating and $45.00 price target on Momenta Pharmaceuticals (NASDAQ: MNTA)
[Can't access remainder.]
My bet would be to use the voucher with Necuparanib. I realize that this is a big IF, however, we should know more at the 2Q earnings/CC within 2 weeks.
CW did state -
In experiments, heparin drugs have shown up to 4X (the power) to block the virus compared to GILEAD'S Remdesivir.
If Necuparanib shows similar benefits, it would have several benefits over other approaches being similarly tested:
1. Necuparanib designed as a low weight Heparin which could be nebulized to the lungs, if required.
2. Most Heparins are anti-coagulant. Our agent was designed as a non-heparin which can be given in high doses for cancer patients.
3. Our agent has a full toxicology package & has established a full GMP manufacturing supply chain for drug substance & drug products
plus good tolerability in phases 1 & 2 clinical trials. Therefore, this can move faster than others now being tested.
If this agent shows promise in the labs, we will consider to accelerate with government agencies, etc. to get this in the clinic.
Under the best circumstances with the voucher & once again a big IF, Necuparanib could be approved faster than Moderna's COVID vaccine -
Phase 3 clinical trial of investigational vaccine for COVID-19 begins....27 JULY
Multi-site trial to test candidate developed by Moderna and NIH.
https://www.nih.gov/news-events/news-releases/phase-3-clinical-trial-investigational-vaccine-covid-19-begins
Thanks, jbog -
Regulatory Explainer: Everything You Need to Know About FDA’s Priority Review Vouchers
Posted 25 February 2020
https://www.raps.org/regulatory-focus/news-articles/2017/12/regulatory-explainer-everything-you-need-to-know-about-fdas-priority-review-vouchers
Momenta Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Nipocalimab in HDFN
07/28/2020
CAMBRIDGE, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced that its novel drug candidate, nipocalimab, has received rare pediatric disease designation from the U.S. Food and Drug Administration (FDA) for the prevention of hemolytic disease of the fetus and newborn (HDFN). Additionally, FDA granted nipocalimab orphan drug designation in HDFN. HDFN is a serious blood disorder in a fetus or newborn that occurs when red blood cell incompatibility exists between the blood types of a mother and fetus in utero.
“In HDFN, a mismatch in parent’s blood group antigens causes the mother’s immune system to recognize the fetus’ red blood cells as foreign. This results in the development of pathogenic antibodies that transfer across the placenta during pregnancy and attack the baby’s red blood cells causing fetal anemia which can be fatal,” said Santiago Arroyo, M.D., Ph.D., Senior Vice President of Development and Chief Medical Officer of Momenta Pharmaceuticals. “The standard treatment for HDFN involves intrauterine blood transfusions which are invasive and can be associated with significant complications, including in some cases fetal mortality.
Receiving this designation emphasizes the need for a non-invasive, safe, and effective treatment option. Our trial in this indication is progressing and we are committed to working with the FDA to bring this option to families who experience this devastating disease as soon as possible.”
Rare pediatric disease designation is granted by the FDA to drug candidates addressing serious or life-threatening diseases or conditions that affect fewer than 200,000 children in the U.S. Under the FDA's Rare Pediatric Disease Priority Review Voucher program, a sponsor who receives an approval for a drug or biologic for a "rare pediatric disease" may qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product. For more information about the rare pediatric disease program, please visit the FDA website at www.fda.gov.
https://www.momentapharma.com/investors-and-news/press-releases/press-releases-details/2020/Momenta-Pharmaceuticals-Announces-FDA-Rare-Pediatric-Disease-Designation-for-Nipocalimab-in-HDFN/default.aspx
Hey Fun - stay safe - Douglas, 130 MPH winds -
In anticipation of Douglas passing near or over the islands, Hawaii Gov. David Ige issued a state of emergency declaration on Thursday.
Hurricane watches have also been issued for Maui and the Big Island.
“Our top priority is always the safety, health and well-being of our residents and visitors. Please take immediate steps to protect your families, loved ones, employees and property,” Ige said in a news release.
According to Hawaii News Now, officials are looking at opening emergency shelters, but due to the coronavirus pandemic, some residents may have to shelter in place at home due to a reduced capacity at shelters.
“We have limited shelter space due to COVID-19 guidelines, so we are urging the public to make preparations now to possible shelter in place at your home, or a family or friend’s home,” Maui Emergency Management Agency administrator Herman Andaya told Hawaii News Now.
https://www.accuweather.com/en/hurricane/hawaii-bracing-for-rare-strike-from-hurricane-as-douglas-creeps-closer/782455
As stated, FWIW - AGAIN -
15 June summary/transcript on possible COVID-19/Necuparanib treatment -
CW - ....we believe we have an agent in our portfolio which may have a potential option for COVID. We were contacted by one of our founders, Ganesh Kaundinya, about the potential of Necuparanib to block the binding of COVID-19. Ganesh was part of a panel of experts' discussions in the roll of sugars to fight the virus. In experiments, heparin drugs have shown up to 4X (the power) to block the virus compared to GILEAD'S Remdesivir.
If Necuparanib shows similar benefits, it would have several benefits over other approaches being similarly tested:
1. Necuparanib designed as a low weight Heparin which could be nebulized to the lungs, if required.
2. Most Heparins are anti-coagulant. Our agent was designed as a non-heparin which can be given in high doses for cancer patients.
3. Our agent has a full toxicology package & has established a full GMP manufacturing supply chain for drug substance & drug products plus good tolerability in phases 1 & 2 clinical trials. Therefore, this can move faster than others now being tested.
If this agent shows promise in the labs, we will consider to accelerate with government agencies, etc. to get this in the clinic.
Necuparanib, a multi-targeting heparan sulfate mimetic, targets tumor and stromal compartments in pancreatic cancer (American Association for Cancer Research - 6 November 2018)
Abstract
Pancreatic cancer has an abysmal five year survival rate of 8 %, making it a deadly disease with a need for novel therapies. Here we describe a multi-targeting heparin-based mimetic, necuparanib, and its anti-tumor activity in both in vitro and in vivo models of pancreatic cancer. Necuparanib reduced tumor cell proliferation and invasion in a 3-dimensional (3D) culture model; in vivo it extended survival and reduced metastasis. Furthermore, proteomic analysis demonstrated that necuparanib altered the expression levels of multiple proteins involved in cancer-driving pathways including organ development, angiogenesis, proliferation, genomic stability, cellular energetics, and invasion & metastasis. One protein family known to be involved in invasion & metastasis and altered by necuparanib treatment was the matrix metalloprotease (MMP) family. Necuparanib reduced metalloproteinase 1 (MMP1) and increased tissue inhibitor of metalloproteinase 3 (TIMP3) protein levels and was found to increase RNA expression of TIMP3. MMP enzymatic activity was also found to be reduced in the 3D model. Finally, we confirmed necuparanib's in vivo activity by analyzing plasma samples of patients enrolled in a Phase I/II study in patients with metastatic pancreatic cancer; treatment with necuparanib plus standard of care significantly increased TIMP3 plasma protein levels. Together, these results demonstrate necuparanib acts as a broad multi-targeting therapeutic with in vitro and in vivo anti-invasive and anti-metastatic activity.
https://mct.aacrjournals.org/content/early/2018/11/06/1535-7163.MCT-18-0417
PDF version -
Excerpts:
Necuparanib, a heparin mimetic, is rationally designed to have reduced anti-coagulation activity while retaining the ability to bind and sequester multiple heparin-binding growth factors....
We have previously reported an in-depth analysis of necuparanib’s properties, including an over 10 fold reduction anti-coagulation and various anti-tumor properties including a reduction in angiogenesis, tumor burden and tumor metastasis in a breast cancer model and in several metastases models.
As necuparanib advanced into the clinic, phase I demonstrated acceptable patient tolerability of necuparanib in combination with nab-paclitaxel and gemcitabine therapy (49). However, a routine interim analysis of the phase II study in patients with metastatic pancreatic cancer revealed that adding necuparanib to the standard of care did not sufficiently increase therapeutic efficacy to warrant continuation of the study. As many proven therapies have failed to improve survival in metastatic pancreatic cancer (50,51), we remain hopeful that necuparanib may be a promising therapeutic opportunity for earlier stage pancreatic cancer and other cancers.
https://mct.aacrjournals.org/content/early/2018/11/06/1535-7163.MCT-18-0417.full-text.pdf
Deep dive into same article -
In a binding assay, the researchers found that heparin bound to the trimeric SARS-CoV-2 spike protein at 73 picomoles, a measure of the interaction between the two molecules.
"That's exceptional, extremely tight binding," said Jonathan Dordick, a chemical and biological engineering professor at Rensselaer who is collaborating with Linhardt to develop the decoy strategy. "It's hundreds of thousands of times tighter than a typical antibody antigen. Once it binds, it's not going to come off."
Internationally recognized for his creation of synthetic heparin, Linhardt said that, in reviewing sequencing data for SARS-CoV-2, the team recognized certain motifs on the spike protein and strongly suspected it would bind to heparin. In addition to the direct binding assay, the team tested how strongly three heparin variants -- including a non-anticoagulant low molecular weight heparin -- bind to SARS-CoV-2, and used computational modeling to determine the specific sites where the compounds bind to the virus. All the results confirm heparin as a promising candidate for the decoy strategy. The researchers have subsequently initiated work on assessments of antiviral activity and cytotoxicity in mammalian cells.
Common FDA-approved drug may effectively neutralize virus that causes COVID-19
Heparin could be used as a decoy to prevent SARS-CoV-2 from infecting human cells
Date:
July 15, 2020
Source:
Rensselaer Polytechnic Institute
Summary:
A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to new research.
This makes it a decoy, which might be introduced into the body using **a nasal spray or nebulizer and run interference to lower the odds of infection. Similar decoy strategies have already shown promise in curbing other viruses, including influenza A, Zika, and dengue.
"This approach could be used as an early intervention to reduce the infection among people who have tested positive, but aren't yet suffering symptoms.
https://www.sciencedaily.com/releases/2020/07/200715123203.htm
**CW spoke such on 15 June CC.
Study these words carefully -
15 June summary/transcript on possible COVID-19/Necuparanib treatment -
CW - ....we believe we have an agent in our portfolio which may have a potential option for COVID. We were contacted by one of our founders, Ganesh Kaundinya, about the potential of Necuparanib to block the binding of COVID-19. Ganesh was part of a panel of experts' discussions in the roll of sugars to fight the virus. In experiments, heparin drugs have shown up to 4X (the power) to block the virus compared to GILEAD'S Remdesivir.
If Necuparanib shows similar benefits, it would have several benefits over other approaches being similarly tested:
1. Necuparanib designed as a low weight Heparin which could be nebulized to the lungs, if required.
2. Most Heparins are anti-coagulant. Our agent was designed as a non-heparin which can be given in high doses for cancer patients.
3. Our agent has a full toxicology package & has established a full GMP manufacturing supply chain for drug substance & drug products plus good tolerability in phases 1 & 2 clinical trials. Therefore, this can move faster than others now being tested.
If this agent shows promise in the labs, we will consider to accelerate with government agencies, etc. to get this in the clinic.
_______________________________
Gilead sets price of coronavirus drug remdesivir at $3,120 as Trump administration secures supply for 500,000 patients
https://www.washingtonpost.com/business/2020/06/29/gilead-sciences-remdesivir-cost-coronavirus/
_______________________________
Latest MNTA career listing excerpt re: NECUPARANIB??
Senior Director, Regulatory AffairsQualifications -
Experience having managed significant accelerations
https://osv-momentapharma.wd1.myworkdayjobs.com/en-US/MomentaCareers/job/Cambridge-MA-Bent/Senior-Director--Regulatory-Affairs_REQ-000466
METHOD OF MANUFACTURING A THERAPEUTIC PROTEIN - 2020-7-13
BACKGROUND OF THE INVENTION
The production of therapeutic proteins using mammalian cell expression systems is of growing importance within the biotechnology industry. Various culture and transfection systems have been described, but each has significant limitations.
SUMMARY OF THE INVENTION
The invention described herein is based, in part, on the discovery that the combination of cholesterol-auxotrophic cells with one or more additional selection markers can be exploited in methods of manufacturing therapeutic proteins....
https://worldwide.espacenet.com/publicationDetails/description?CC=PL&NR=3289092T3&KC=T3&FT=D&ND=3&date=20200713&DB=EPODOC&locale=en_EP
FYI - if you are near Boston, you might want to make an appointment
https://orthopedics.brighamandwomens.org/?cmp=orpsr&utm_source=google&utm_medium=cpc&utm_campaign=2020vv_ortho&utm_content=general_ma_e_&gclid=EAIaIQobChMIq9q0jIrN6gIVk4zICh09XwsXEAAYASAAEgJBkvD_BwE&gclsrc=aw.ds
A friend had knee replacement there last week. She was convalescing with only minor pain after 2 days.
Be persistent in demanding the surgery.
Good luck!
New MNTA blockbuster EPO drug patent application dated 2020-7-9
METHODS OF PRODUCING USTEKINUMAB
Abstract:
Methods of manufacturing an ustekinumab product with a target level of one or more glycans are described.
https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20200709&CC=WO&NR=2020142275A1&KC=A1
Ustekinumab sold under the brand name Stelara, is a human monoclonal antibody used to treat psoriasis. It is also approved to treat Crohn's disease in the United States, Israel and Australia, and ulcerative colitis in the U.S., and in the European Union (EU) among people who have not responded to more traditional treatments. It was found not effective for multiple sclerosis.
https://en.wikipedia.org/wiki/Ustekinumab
J&J's top-seller Stelara looks set to expand into ulcerative
colitis
Last year, the blockbuster exceeded $4 billion in worldwide sales and has netted $2.4 billion through the first half of 2018.
https://www.biopharmadive.com/news/jjs-top-seller-stelara-looks-set-to-expand-into-ulcerative-colitis/539228/
**Since biosimilars are no longer their forte, a partnership might be on the horizon.